156 stories across all digests
Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
Researchers engineered PLGA nanocomplexes functionalized with iRGD tumor-penetrating peptides to deliver paclitaxel combined with medicinal fungus extract, targeting the PDCD4 gene to overcome drug resistance.
A new study identified a potential link between semaglutide use and a rare dermatological pain syndrome. Researchers also referenced Phase 2 retatrutide data as part of broader incretin safety analysis.
New data shows the first oral CGRP antagonist ubrogepant demonstrates better efficacy when administered during mild pain rather than waiting for moderate-to-severe migraine pain.
A study of ~175,000 Type 1 diabetes patients found GLP-1 receptor agonists reduced five-year cardiovascular event risk by 15% and end-stage kidney disease by 19%, with no increase in severe hypoglycemia. Published in Nature Medicine.
A research review characterizes TB-500 and BPC-157 as distinct informational modulators, with TB-500 linked to thymosin beta-4 biology and BPC-157 acting as a localized signaling stabilizer.
Eric Topol of Scripps Research called peptide data "woefully minuscule," warning about impurities, random dosing, and dangerous stacking of unproven compounds from gray-market sources.
Findings presented at The Liver Meeting show retatrutide cleared fatty liver disease in more than 85% of patients with obesity, dramatically expanding its therapeutic profile beyond weight loss.
Lilly and startup Baseline Therapeutics are investigating GLP-1 RAs for alcohol and substance use disorders. A large VA study found GLP-1s associated with reduced substance abuse risk, in a therapeutic area projected to reach $12.4B by 2033.
CancerNetwork reviews the latest evidence on thyroid cancer risk associated with GLP-1 RAs like Ozempic and Mounjaro, providing clinicians with an updated risk-benefit assessment for long-term prescribing.
GLP-1 RAs, particularly semaglutide, are showing robust clinical data for liver disease with significant rates of disease resolution and improvement in liver fibrosis.
The thymus — source of thymosin peptides including Thymosin Alpha-1 — has become an emerging target for healthspan, longevity, and precision oncology research.
A BMJ-published study of over 600,000 US veterans found GLP-1 medications tied to reduced risk of substance use disorders across all major addictive substances, plus reduced overdose and death risk.
New research shows semaglutide, dulaglutide, and tirzepatide can increase testosterone levels in men with obesity, adding another ancillary benefit to the GLP-1 portfolio.
Kumamoto University's DNP cyclic peptide system achieved roughly one-third to nearly half the effectiveness of injected insulin in animal studies — a major advance for oral insulin delivery.
Clinical insights suggest GLP-1 agonists may pose extra risks for Ehlers-Danlos Syndrome patients, as delayed gastric emptying can exacerbate GI connective tissue vulnerabilities.
Dermatology Times Q&A explores advances in GHK-Cu delivery for skincare, discussing how the peptide complexes with copper in human plasma and new formulation approaches to improve topical efficacy.
A condition-by-condition guide examining what's proven, promising, and untested for GLP-1 drugs beyond weight loss — covering cardiovascular disease, addiction, kidney disease, and neurological conditions.
Stanford researchers developed a method converting peptide sequences into DNA for standard sequencing, published in Nature Biotechnology. Could dramatically accelerate peptide drug discovery.